Phase 1 Crossover Study to Assess the Effects of SQ109 on QTc Interval in Healthy Subjects
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 14 May 2014
Price : $35 *
At a glance
- Drugs SQ 109 (Primary) ; Moxifloxacin
- Indications Crohn's disease; Duodenal ulcer; Helicobacter infections; Mycobacterial infections; Mycoses; Tuberculosis
- Focus Adverse reactions
- 20 Mar 2014 Trial status changed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 13 Feb 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
- 28 Jun 2013 New trial record